2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T9b1,Cutaneous vasculitis (CV) is a heterogenous and severe complication of primary Sjögren disease, often indicating systemic involvement and poor prognosis. Understanding its characteristics and outcomes is essential for patient management. To describe the clinical features, management, and prognosis of different CV types in patients with Sjögren disease. This retrospective multicenter cohort study included patients with Sjögren disease and CV from pathology departments of 3 university hospitals in Paris, France (2011-2021), and a national case call. Patients met American College of Rheumatology/European League Against Rheumatism criteria and were matched 1:2 to controls patients with Sjögren disease but without CV. Data were collected and analyzed between March 2023 and March 2025. Presence of CV classified using the Chapel Hill classification dermatological addendum. Demographics, clinical characteristics, immunological parameters, and received treatments were recorded. Primary outcomes were lymphoma occurrence and mortality risk, as well therapeutic response. Among 54 patients with CV and Sjögren disease (median [IQR] age at diagnosis of CV, 42 [27.7-56.0] years; 49 [91%] female), CV was more frequently classified as cryoglobulinemic vasculitis (29 patients [57%]) or hypergammaglobulinemic vasculitis (15 patients [28%]). Compared to controls, patients with Sjögren disease and CV had a higher lymphoma incidence (12 of 54 [13%] vs 4 of 108 [4%]; P = .04). Compared to other types of CV, type II cryoglobulinemic vasculitis was associated with increased mortality or lymphoma risk (hazard ratio, 6.8; 95% CI, 1.8-25.5; P = .005), higher ESSDAI (EULAR Sjögren Syndrome Disease Activity Index) scores (median [IQR], 15 [12-23]; P = .005), and more frequent kidney involvement (7 of 24 patients [29%] vs 1 of 25 patients [4%]; P = .02) and peripheral nervous system involvement (15 of 24 patients [63%] vs 3 of 25 patients [12%]; P < .001). Rituximab-based therapy showed no survival benefit for patients with type II cryoglobulinemic vasculitis compared to other treatments. In this cohort study, among CV subtypes in patients with Sjögren disease, only type II cryoglobulinemic vasculitis was associated with poor prognosis. Early recognition and monitoring for systemic complications, particularly lymphoma, are essential in these patients. Further research is needed to evaluate optimal treatment strategies for improving outcomes.31:Tcf9,ImportanceCutaneous vasculitis (CV) is a heterogenous and severe complication of primary Sjögren disease, often indicating systemic involvement and poor prognosis. Understanding its characteristics and outcomes is essential for patient management.ObjectiveTo describe the clinical features, management, and prognosis of different CV types in patients with Sjögren disease.Design, Setting, and ParticipantsThis retrospective multicenter cohort study included patients with Sjögren disease and CV from pathology departments of 3 university hospitals in Paris, France (2011-2021), and a national case call. Patients met American College of Rheumatology/European League Against Rheumatism criteria and were matched 1:2 to controls patients with Sjögren disease but without CV. Data were collected and analyzed between March 2023 and March 2025.ExposurePresence of CV classified using the Chapel Hill classification dermatological addendum.Main Outcomes and MeasuresDemographics, clinical characteristics, immunological parameters, and received treatments were recorded. Primary outcomes were lymphoma occurrence and mortality risk, as well therapeutic response.ResultsAmong 54 patients with CV and Sjögren disease (median [IQR] age at diagnosis of CV, 42 [27.7-56.0] years; 49 [91%] female), CV was more frequently classified as cryoglobulinemic vasculitis (29 patients [57%]) or hypergammaglobulinemic vasculitis (15 patients [28%]). Compared to controls, patients with Sjögren disease and CV had a higher lymphoma incidence (12 of 54 [13%] vs 4 of 108 [4%]; P = .04). Compared to other types of CV, type II cryoglobulinemic vasculitis was associated with increased mortality or lymphoma risk (hazard ratio, 6.8; 95% CI, 1.8-25.5; P = .005), higher ESSDAI (EULAR Sjögren Syndrome Disease Activity Index) scores (median [IQR], 15 [12-23]; P = .005), and more frequent kidney involvement (7 of 24 patients [29%] vs 1 of 25 patients [4%]; P = .02) and peripheral nervous system involvement (15 of 24 patients [63%] vs 3 of 25 patients [12%]; P &lt; .001). Rituximab-based therapy showed no survival benefit for patients with type II cryoglobulinemic vasculitis compared to other treatments.Conclusions and RelevanceIn this cohort study, among CV subtypes in patients with Sjögren disease, only type II cryoglobulinemic vasculitis was associated with poor prognosis. Early recognition and monitoring for systemic complications, particularly lymphoma, are essential in these patients. Further research is needed to evaluate optimal treatment strategies for improving outcomes.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Cutaneous Vasculitis: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Cutaneous Vasculitis (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Cutaneous%20Vasculitis\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Cutaneous Vasculitis\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Cutaneous%20Vasculitis\"}]}}"}}]],["$","$L2f",null,{"title":"Cutaneous Vasculitis: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Cutaneous Vasculitis with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.2340/actadv.v106.adv-2025-0308","pmid":"42516097","title":"Persistent SARS-CoV-2 Spike Protein in Vasculitic Skin Lesions after Infection or mRNA Vaccination: A Retrospective Case control Immunofluorescence Study","journal_title":"Acta Dermato-Venereologica","journal_issn":"1651-2057","published_at":"2026-07-28T00:00:00.000Z","url":"https://doi.org/10.2340/actadv.v106.adv-2025-0308","source_score":2,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-31T13:37:19.769Z","updated_at":"2026-07-31T13:37:19.769Z","tags":[{"paper_doi":"10.2340/actadv.v106.adv-2025-0308","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2025-0308","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2025-0308","tag_type":"condition","value":"Cutaneous Vasculitis","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2025-0308","tag_type":"condition","value":"Leukocytoclastic Vasculitis","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2025-0308","tag_type":"condition","value":"Post-COVID-19 Condition","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2025-0308","tag_type":"generic","value":"SARS-CoV-2 spike protein","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2025-0308","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2025-0308","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2025-0308","tag_type":"modality","value":"mRNA Vaccine","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2025-0308","tag_type":"sample_size","value":"n=9","value_numeric":9},{"paper_doi":"10.2340/actadv.v106.adv-2025-0308","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2025-0308","tag_type":"study_design","value":"Retrospective Case-Control Study","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2025-0308","tag_type":"warning","value":"Immunofluorescence antibody specificity for SARS-CoV-2 spike protein in FFPE tissue was not independently validated in this paper.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2025-0308","tag_type":"warning","value":"One patient (V5) in the vasculitis cohort is listed in Table I as spike-negative, but the abstract states all 9 were positive — a minor inconsistency in the paper that could not be resolved from the text alone.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2025-0308","tag_type":"warning","value":"Sample size is very small (n=9 cases, n=6 controls); findings should be considered hypothesis-generating only.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2025-0308","tag_type":"warning","value":"The study does not establish causality between spike persistence and vasculitis; temporal association only.","value_numeric":null}],"summaries":{"what_studied":"This retrospective case-control study investigated whether SARS-CoV-2 spike protein persists in lesional vascular endothelial cells in 9 patients with persistent or delayed-onset cutaneous vasculitis (4 post-COVID-19 infection, 5 post-mRNA vaccination), with skin biopsies analyzed by immunofluorescence; controls included 3 pre-pandemic leukocytoclastic vasculitis and 3 healthy post-infection/post-vaccination skin samples.","key_result":"Spike protein was detected in vascular endothelial cells in all 9 vasculitis patients — including cases up to 5 months after infection and up to 18 months after vaccination — but was absent in all 6 controls (pre-pandemic vasculitis and healthy post-COVID/post-vaccination skin).","limitations":"- Very small sample size (n=9 cases), reflecting the rarity of documented temporal associations.\n- Retrospective design with potential inaccuracies in timing; asymptomatic prior infections cannot be excluded.\n- Direct immunofluorescence data were not systematically available, limiting vasculitis subclassification; most patients had only a single biopsy time point, preventing assessment of spike persistence kinetics.","practice_takeaway":"In patients presenting with vasculitic skin lesions weeks to months after COVID-19 infection or mRNA vaccination, SARS-CoV-2 spike protein may still be detectable in dermal microvascular endothelium — consider this etiology in delayed or persistent cutaneous vasculitis with a relevant exposure history.\nCausality is not established, and larger prospective studies are needed before this finding changes clinical management."}},{"doi":"10.1016/j.clindermatol.2026.07.019","pmid":"42521049","title":"Erythema Elevatum Diutinum","journal_title":"Clinics in Dermatology","journal_issn":"0738-081X","published_at":"2026-07-28T00:00:00.000Z","url":"https://doi.org/10.1016/j.clindermatol.2026.07.019","source_score":1,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-04T18:17:49.614Z","updated_at":"2026-08-04T18:17:49.614Z","tags":[{"paper_doi":"10.1016/j.clindermatol.2026.07.019","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.019","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.019","tag_type":"condition","value":"Cutaneous Vasculitis","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.019","tag_type":"condition","value":"Erythema Elevatum Diutinum","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.019","tag_type":"condition","value":"HIV Infection","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.019","tag_type":"condition","value":"IgA Monoclonal Gammopathy","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.019","tag_type":"condition","value":"Multiple Myeloma","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.019","tag_type":"condition","value":"Non-Hodgkin Lymphoma","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.019","tag_type":"generic","value":"dapsone","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.019","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.019","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.019","tag_type":"modality","value":"Corticosteroid","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.019","tag_type":"modality","value":"Immunosuppressive Agent","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.019","tag_type":"modality","value":"Sulfone Antibiotic","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.019","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.019","tag_type":"warning","value":"Age group tagged as 'adult' by inference from typical EED epidemiology; the paper does not explicitly state an age population.","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.019","tag_type":"warning","value":"The DOI and publication date (July 2026) are recent; clinicians should verify that no updated guidelines have superseded the dapsone-first recommendation.","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.019","tag_type":"warning","value":"This is a narrative review with no original patient data, sample size, or comparative outcomes — clinical guidance is expert/consensus-level only.","value_numeric":null}],"summaries":{"what_studied":"This review covers the clinical presentation, histology, associated systemic conditions, and management of erythema elevatum diutinum (EED), a rare chronic cutaneous vasculitis.","key_result":"EED is strongly associated with systemic diseases — including IgA monoclonal gammopathy, multiple myeloma, non-Hodgkin lymphoma, HIV, and streptococcal infection. First-line treatment is dapsone; corticosteroids and immunosuppressives are used for resistant cases. Lesions can persist for decades, but treating the underlying condition can alter disease course.","limitations":"No specific patient data, outcomes, or comparative treatment efficacy figures are reported — this is a narrative review without original trial data or sample population.","practice_takeaway":"When EED is diagnosed, actively screen for serious underlying conditions such as hematologic malignancies and HIV, as addressing them may improve skin disease. Dapsone remains the go-to first-line therapy for the skin lesions themselves."}},{"doi":"10.1016/j.clindermatol.2026.07.026","pmid":"42508548","title":"Neutrophilic Dermatoses","journal_title":"Clinics in Dermatology","journal_issn":"0738-081X","published_at":"2026-07-27T00:00:00.000Z","url":"https://doi.org/10.1016/j.clindermatol.2026.07.026","source_score":1,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-04T18:17:49.924Z","updated_at":"2026-08-04T18:17:49.924Z","tags":[{"paper_doi":"10.1016/j.clindermatol.2026.07.026","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.026","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.026","tag_type":"condition","value":"Bazex Syndrome","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.026","tag_type":"condition","value":"Behçet Disease","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.026","tag_type":"condition","value":"Cutaneous Vasculitis","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.026","tag_type":"condition","value":"Erythema Elevatum Diutinum","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.026","tag_type":"condition","value":"Neutrophilic Dermatoses","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.026","tag_type":"condition","value":"Neutrophilic Eccrine Hidradenitis","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.026","tag_type":"condition","value":"Paraneoplastic Dermatosis","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.026","tag_type":"condition","value":"Pyoderma Gangrenosum","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.026","tag_type":"condition","value":"Schnitzler Syndrome","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.026","tag_type":"condition","value":"Subcorneal Pustular Dermatosis","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.026","tag_type":"condition","value":"Sweet Syndrome","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.026","tag_type":"condition","value":"VEXAS Syndrome","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.026","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.026","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.026","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.026","tag_type":"warning","value":"Bazex syndrome in this context refers to the paraneoplastic acrokeratosis variant, not Bazex-Dupré-Christol syndrome — clinicians should confirm which is meant in clinical contexts.","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.026","tag_type":"warning","value":"No sample size applicable — this is a narrative review with no original patient cohort.","value_numeric":null},{"paper_doi":"10.1016/j.clindermatol.2026.07.026","tag_type":"warning","value":"The paper covers a broad, heterogeneous group of conditions; evidence quality likely varies considerably across individual disorders discussed.","value_numeric":null}],"summaries":{"what_studied":"This review evaluates the clinical and histopathologic features of neutrophilic dermatoses — including Sweet syndrome, pyoderma gangrenosum, VEXAS syndrome, and others — as cutaneous manifestations of underlying malignancy, along with current treatment options.","key_result":"Multiple neutrophilic dermatoses (e.g., Sweet syndrome, pyoderma gangrenosum, neutrophilic eccrine hidradenitis, subcorneal pustular dermatosis, erythema elevatum diutinum, Behçet's disease, Bazex syndrome, VEXAS syndrome) can serve as cutaneous markers of occult or overt malignancy, and may precede the cancer diagnosis.","limitations":"Narrative review without systematic methodology or meta-analysis; no original patient data or quantitative outcomes reported; conditions reviewed are rare and heterogeneous, limiting generalizable conclusions.","practice_takeaway":"When a patient presents with a sterile neutrophilic dermatosis, consider workup for an underlying malignancy — especially hematologic — as the skin finding may precede the cancer diagnosis. Early recognition can prompt timely systemic evaluation and improve outcomes."}},{"doi":"10.1001/jamadermatol.2025.2665","pmid":"40939197","title":"Cutaneous Vasculitis in Primary Sjögren Disease","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2025-09-12T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2025.2665","source_score":42,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-10-19","doi":"10.1001/jamadermatol.2025.2665","days":"30","issn":"2168-6068","rank":"10","field":"Clinical Medicine","score":"42","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2025.2665","title":"Cutaneous Vasculitis in Primary Sjögren Disease.","journal":"JAMA dermatology","methods":"","results":"Among 54 patients with CV and Sjögren disease (median [IQR] age at diagnosis of CV, 42 [27.7-56.0] years; 49 [91%] female), CV was more frequently classified as cryoglobulinemic vasculitis (29 patients [57%]) or hypergammaglobulinemic vasculitis (15 patients [28%]). Compared to controls, patients with Sjögren disease and CV had a higher lymphoma incidence (12 of 54 [13%] vs 4 of 108 [4%]; P = .04). Compared to other types of CV, type II cryoglobulinemic vasculitis was associated with increased mortality or lymphoma risk (hazard ratio, 6.8; 95% CI, 1.8-25.5; P = .005), higher ESSDAI (EULAR Sjögren Syndrome Disease Activity Index) scores (median [IQR], 15 [12-23]; P = .005), and more frequent kidney involvement (7 of 24 patients [29%] vs 1 of 25 patients [4%]; P = .02) and peripheral nervous system involvement (15 of 24 patients [63%] vs 3 of 25 patients [12%]; P < .001). Rituximab-based therapy showed no survival benefit for patients with type II cryoglobulinemic vasculitis compared to other treatments.","abstract":"$30","keywords":[],"pubmed_id":"40939197","conclusions":"","publication_date":"2025-09-12T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2025.2665","URL":"https://doi.org/10.1001/jamadermatol.2025.2665","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2837170/jamadermatology_breillat_2025_br_250006_1760475197.01133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"1057","type":"journal-article","issue":"10","score":1,"title":["Cutaneous Vasculitis in Primary Sjögren Disease"],"author":[{"given":"Paul","family":"Breillat","sequence":"first","affiliation":[{"name":"Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d’Ile de France, de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP)-CUP, Université de Paris Cité, Paris, France"},{"name":"INSERM, U970, Paris Centre de Recherche Cardiovasculaire (PARCC), Paris, France"}]},{"given":"Véronique","family":"Le Guern","sequence":"additional","affiliation":[{"name":"Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d’Ile de France, de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP)-CUP, Université de Paris Cité, Paris, France"}]},{"given":"Thomas","family":"d’Humières","sequence":"additional","affiliation":[{"name":"Department of Physiology, FHU SENEC, Henri Mondor Hospital, Assistance Publique Hôpitaux de Paris, INSERM IMRB U955, Université Paris Est, Créteil, France"}]},{"given":"Maxime","family":"Battistella","sequence":"additional","affiliation":[{"name":"Department of Pathology, AP-HP, Saint-Louis Hospital, Université Paris Cité, Paris France"}]},{"given":"Paul","family":"Legendre","sequence":"additional","affiliation":[{"name":"Clinical Immunology Department, Centre Hospitalier du Mans, Le Mans, France"}]},{"given":"Cédric","family":"Lenormand","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hôpital Civil-Hôpitaux Universitaires de Strasbourg, Strasbourg, France"}]},{"given":"Diane","family":"Kottler","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Caen University Hospital, Caen, France"}]},{"given":"Alexis","family":"Mathian","sequence":"additional","affiliation":[{"name":"Médecine Interne 2, AP-HP, Hôpital Pitié Salpetrière, Sorbonne Université, Faculté de Médecine, Paris, France"}]},{"given":"Marie","family":"Jachiet","sequence":"additional","affiliation":[{"name":"Department of Dermatology, AP-HP, Saint-Louis Hospital, Université Paris Cité, Paris France"}]},{"given":"Jihane","family":"El Khalifa","sequence":"additional","affiliation":[{"name":"Dermatology Department, Bichat, AP-HP, Paris, France"}]},{"given":"Thibault","family":"Mahévas","sequence":"additional","affiliation":[{"name":"Department of Dermatology, AP-HP, Saint-Louis Hospital, Université Paris Cité, Paris France"}]},{"given":"Chloé","family":"Comarmond","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Département Médico-Universitaire INVICTUS, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Nord–Université Paris Cité, Paris, France"}]},{"given":"Damien","family":"Sene","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Département Médico-Universitaire INVICTUS, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Nord–Université Paris Cité, Paris, France"}]},{"given":"Zahir","family":"Amoura","sequence":"additional","affiliation":[{"name":"Médecine Interne 2, AP-HP, Hôpital Pitié Salpetrière, Sorbonne Université, Faculté de Médecine, Paris, France"}]},{"given":"Jacques-Eric","family":"Gottenberg","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, CHU Hautepierre, Strasbourg, France"}]},{"given":"Luc","family":"Mouthon","sequence":"additional","affiliation":[{"name":"Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d’Ile de France, de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP)-CUP, Université de Paris Cité, Paris, France"}]},{"given":"Jean-David","family":"Bouaziz","sequence":"additional","affiliation":[{"name":"Department of Dermatology, AP-HP, Saint-Louis Hospital, Université Paris Cité, Paris France"}]},{"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Université Paris-Saclay, INSERM UMR1184, Le Kremlin-Bicêtre, France"}]},{"given":"François","family":"Chasset","sequence":"additional","affiliation":[{"name":"Dermatology and Allergology, AP-HP, Hôpital Tenon Sorbonne Université, Faculté de Médecine, Paris, France"},{"name":"INSERM U1135, CIMI, Paris, France"}]},{"given":null,"family":null,"sequence":"additional","affiliation":[]},{"given":"Joelle","family":"Benessiano","sequence":"additional","affiliation":[{"name":"and the ASSESS Study Investigators"}]},{"given":"Emmanuelle","family":"Dernis","sequence":"additional","affiliation":[{"name":"and the ASSESS Study Investigators"}]},{"given":"Valerie","family":"Devauchelle-Pensec","sequence":"additional","affiliation":[{"name":"and the ASSESS Study Investigators"}]},{"given":"Philippe","family":"Dieude","sequence":"additional","affiliation":[{"name":"and the ASSESS Study Investigators"}]},{"given":"Jean-Jacques","family":"Dubost","sequence":"additional","affiliation":[{"name":"and the ASSESS Study Investigators"}]},{"given":"Anne-Laure","family":"Fauchais","sequence":"additional","affiliation":[{"name":"and the ASSESS Study Investigators"}]},{"given":"Eric","family":"Hachulla","sequence":"additional","affiliation":[{"name":"and the ASSESS Study Investigators"}]},{"given":"Vincent","family":"Goeb","sequence":"additional","affiliation":[{"name":"and the ASSESS Study Investigators"}]},{"given":"Pierre Yves","family":"Hatron","sequence":"additional","affiliation":[{"name":"and the ASSESS Study Investigators"}]},{"given":"Jacques","family":"Morel","sequence":"additional","affiliation":[{"name":"and the ASSESS Study Investigators"}]},{"given":"Claire","family":"Larroche","sequence":"additional","affiliation":[{"name":"and the ASSESS Study Investigators"}]},{"given":"Corinne","family":"Miceli-Richard","sequence":"additional","affiliation":[{"name":"and the ASSESS Study Investigators"}]},{"given":"Gaétane","family":"Nocturne","sequence":"additional","affiliation":[{"name":"and the ASSESS Study Investigators"}]},{"given":"Aleth","family":"Perdriger","sequence":"additional","affiliation":[{"name":"and the ASSESS Study Investigators"}]},{"given":"Xavier","family":"Puéchal","sequence":"additional","affiliation":[{"name":"and the ASSESS Study Investigators"}]},{"given":"Philippe","family":"Ravaud","sequence":"additional","affiliation":[{"name":"and the ASSESS Study Investigators"}]},{"given":"Stephanie","family":"Rist","sequence":"additional","affiliation":[{"name":"and the ASSESS Study Investigators"}]},{"given":"Carinne","family":"Salliot","sequence":"additional","affiliation":[{"name":"and the ASSESS Study Investigators"}]},{"given":"Alain","family":"Saraux","sequence":"additional","affiliation":[{"name":"and the ASSESS Study Investigators"}]},{"given":"Raphaèle","family":"Seror","sequence":"additional","affiliation":[{"name":"and the ASSESS Study Investigators"}]},{"given":"Jean","family":"Sibilia","sequence":"additional","affiliation":[{"name":"and the ASSESS Study Investigators"}]},{"given":"Olivier","family":"Vittecoq","sequence":"additional","affiliation":[{"name":"and the ASSESS Study Investigators"}]},{"given":"Didier","family":"Bessis","sequence":"additional","affiliation":[{"name":"and the ASSESS Study Investigators"}]},{"given":"Nadege","family":"Cordel","sequence":"additional","affiliation":[{"name":"and the ASSESS Study Investigators"}]},{"given":"Dan","family":"Lipsker","sequence":"additional","affiliation":[{"name":"and the ASSESS Study Investigators"}]},{"given":"Charles","family":"Cassius","sequence":"additional","affiliation":[{"name":"and the ASSESS Study Investigators"}]},{"given":null,"family":null,"sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2025,10,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"161","created":{"date-time":"2025-08-06T15:00:38Z","timestamp":1754492438000,"date-parts":[[2025,8,6]]},"indexed":{"date-time":"2025-10-16T00:52:14Z","timestamp":1760575934592,"date-parts":[[2025,10,16]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2837170"}},"subtitle":[],"deposited":{"date-time":"2025-10-15T15:02:31Z","timestamp":1760540551000,"date-parts":[[2025,10,15]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2025,10,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1136/ard.2005.041186","key":"dbr250006r1","year":"2006","issue":"6","author":"Theander","volume":"65","first-page":"796","unstructured":null,"article-title":"Lymphoma and other malignancies in primary Sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors.","journal-title":"Ann Rheum Dis","doi-asserted-by":"publisher"},{"DOI":"10.1093/rheumatology/kew194","key":"dbr250006r2","year":"2016","issue":"8","author":"Retamozo","volume":"55","first-page":"1443","unstructured":null,"article-title":"Cryoglobulinaemic vasculitis at diagnosis predicts mortality in primary Sjögren syndrome: analysis of 515 patients.","journal-title":"Rheumatology (Oxford)","doi-asserted-by":"publisher"},{"DOI":"10.1097/01.md.0000119465.24818.98","key":"dbr250006r3","year":"2004","issue":"2","author":"Ramos-Casals","volume":"83","first-page":"96","unstructured":null,"article-title":"Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients.","journal-title":"Medicine (Baltimore)","doi-asserted-by":"publisher"},{"DOI":"10.1097/BOR.0000000000000668","key":"dbr250006r4","year":"2020","issue":"1","author":"Argyropoulou","volume":"32","first-page":"21","unstructured":null,"article-title":"Common and rare forms of vasculitis associated with Sjögren’s syndrome.","journal-title":"Curr Opin Rheumatol","doi-asserted-by":"publisher"},{"DOI":"10.3109/03009742.2014.923931","key":"dbr250006r5","year":"2015","issue":"1","author":"Quartuccio","volume":"44","first-page":"36","unstructured":null,"article-title":"Clinical and biological differences between cryoglobulinaemic and hypergammaglobulinaemic purpura in primary Sjögren’s syndrome: results of a large multicentre study.","journal-title":"Scand J Rheumatol","doi-asserted-by":"publisher"},{"DOI":"10.1002/art.39859","key":"dbr250006r6","year":"2017","issue":null,"author":"Shiboski","volume":"69","first-page":"35","unstructured":null,"article-title":"2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts.","journal-title":"Arthritis Rheumatol","doi-asserted-by":"publisher"},{"DOI":"10.1002/art.42550","key":"dbr250006r7","year":"2023","issue":"10","author":"Duret","volume":"75","first-page":"1798","unstructured":null,"article-title":"Association between Bruton’s tyrosine kinase gene overexpression and risk of lymphoma in primary Sjögren’s syndrome.","journal-title":"Arthritis Rheumatol","doi-asserted-by":"publisher"},{"DOI":"10.1002/art.40375","key":"dbr250006r8","year":"2018","issue":"2","author":"Sunderkötter","volume":"70","first-page":"171","unstructured":null,"article-title":"Nomenclature of cutaneous vasculitis: dermatologic addendum to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.","journal-title":"Arthritis Rheumatol","doi-asserted-by":"publisher"},{"DOI":"10.1136/annrheumdis-2013-204615","key":"dbr250006r9","year":"2015","issue":"5","author":"Seror","volume":"74","first-page":"859","unstructured":null,"article-title":"Validation of EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI).","journal-title":"Ann Rheum Dis","doi-asserted-by":"publisher"},{"DOI":"10.1182/blood-2002-09-2856","key":"dbr250006r10","year":"2003","issue":"10","author":"Zaja","volume":"101","first-page":"3827","unstructured":null,"article-title":"Efficacy and safety of rituximab in type II mixed cryoglobulinemia.","journal-title":"Blood","doi-asserted-by":"publisher"},{"DOI":"10.1136/annrheumdis-2011-201189","key":"dbr250006r11","year":"2012","issue":"11","author":"Hamza","volume":"71","first-page":"1881","unstructured":null,"article-title":"Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren’s syndrome after B cell depletion therapy.","journal-title":"Ann Rheum Dis","doi-asserted-by":"publisher"},{"DOI":"10.1136/annrheumdis-2021-221604","key":"dbr250006r12","year":"2022","issue":"5","author":"Broeren","volume":"81","first-page":"644","unstructured":null,"article-title":"Proteogenomic analysis of the autoreactive B cell repertoire in blood and tissues of patients with Sjögren’s syndrome.","journal-title":"Ann Rheum Dis","doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2025,10,1]]},"reference-count":12,"published-online":null,"references-count":12,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamadermatol.2025.2665","is_oa":false,"title":"Cutaneous Vasculitis in Primary Sjögren Disease","updated":"2025-08-17T18:46:03+00:00","published_date":"2025-08-06","best_oa_location":null}},"created_at":"2025-10-20T07:02:36.724Z","updated_at":"2025-11-05T07:41:18.588Z","tags":[{"paper_doi":"10.1001/jamadermatol.2025.2665","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2665","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2665","tag_type":"condition","value":"Cutaneous Vasculitis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2665","tag_type":"condition","value":"Primary Sjögren Disease","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2665","tag_type":"generic","value":"rituximab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2665","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2665","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2665","tag_type":"modality","value":"Anti-CD20 Monoclonal Antibody","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2665","tag_type":"sample_size","value":"n=162","value_numeric":162},{"paper_doi":"10.1001/jamadermatol.2025.2665","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2665","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2665","tag_type":"warning","value":"Mortality counts and follow-up duration are not provided in the abstract.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2665","tag_type":"warning","value":"Sample size tag reflects combined cases (n=54) and matched controls (n=108).","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2665","tag_type":"warning","value":"Treatment effects (e.g., rituximab) are nonrandomized and may be confounded.","value_numeric":null}],"summaries":{"what_studied":"A retrospective multicenter cohort of patients with primary Sjögren disease and cutaneous vasculitis (2011-2021) classified by the Chapel Hill dermatologic addendum, matched 1:2 to Sjögren controls without cutaneous vasculitis. Primary outcomes were lymphoma occurrence, mortality risk, and therapeutic response.","key_result":"Lymphoma occurred more often with cutaneous vasculitis vs controls (12/54 [13%] vs 4/108 [4%]; P=.04). Type II cryoglobulinemic vasculitis carried higher mortality or lymphoma risk (HR 6.8; 95% CI, 1.8-25.5; P=.005), higher ESSDAI scores (median 15 [IQR 12-23]; P=.005), and more kidney (7/24 [29%] vs 1/25 [4%]; P=.02) and peripheral nerve involvement (15/24 [63%] vs 3/25 [12%]; P<.001); rituximab-based therapy showed no survival benefit vs other treatments.","limitations":"Retrospective design with small subgroup sizes (e.g., type II cryoglobulinemic vasculitis comparisons 24 vs 25) and pathology/case-call–based inclusion may limit generalizability. Mortality counts and follow-up duration were not reported in the abstract, and treatment comparisons were nonrandomized.","practice_takeaway":"In primary Sjögren disease with cutaneous vasculitis—especially type II cryoglobulinemic—monitor closely for lymphoma and systemic involvement, including kidneys and peripheral nerves. Do not assume a survival advantage with rituximab-based regimens based on these data; focus on early recognition and risk stratification."}}],"initialOffset":4,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Cutaneous Vasculitis"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Cutaneous Vasculitis"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Cutaneous Vasculitis"}}}]]

Papers